Efficacy and Safety of Slow Release Dehydroepiandrosterone (DHEA )

Sponsor
Indiana University
Study ID
NCT07179952
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 50 Years
Healthy Volunteers
Not accepted

Interventions

  • Slow Release DHEA — DRUG
    Slow-release dehydroepiandrosterone capsule
  • Placebo — DRUG
    placebo capsule

Study Details

There is evidence to suggest that DHEA-based treatment could be beneficial to patients with asthma, yet one of the main treatments for asthma (taking glucocorticoids, a hormone that is effective in reducing inflammation), suppresses the production of DHEA. In this study, the investigators want to test and evaluate the safety of DHEA-based treatment.

Key Dates

First listed
Sep 18, 2025
Start date
Jan 1, 2027
Status verified
Feb 2026
Primary completion
Sep 30, 2028
Completion
Sep 30, 2028

Study Design

Enrollment
30 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Active Comparator: Slow Release DHEA
    Subjects will take active capsule 1/day for 4 weeks
  • Placebo Comparator: Placebo
    Subjects will take placebo capsule 1/day for 4 weeks

Primary Outcome Measure

Scores of Asthma Control Test [ Time Frame: From baseline to 12 hours after the final dose of final arm (up to 94 days) ]

Central Contacts

Find similar trials

Nationwide
Asthma trialsPulmonology trialsLung disease trials

Related Studies